Combinatorial Targeting of Leukemia and Stromal Cells Overcomes Fms-like Tyrosine Kinase 3 (FLT3) Inhibitor Resistance in Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Bhattacharya, Seemana [1 ,2 ]
Mu, Hong [1 ,2 ]
Piya, Sujan [1 ,2 ]
Zhang, Weiguo [1 ,2 ]
McQueen, Teresa [1 ,2 ]
Paradiso, Linda [3 ]
Oberkovitz, Galia [4 ]
Benami, Eyal [4 ]
Andreeff, Michael [1 ,2 ]
Borthakur, Gautam [1 ,2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Houston, TX 77030 USA
[3] Strategia Therapeut Inc, 28420 Hardy Toll Rd,Suite 110, Spring, TX USA
[4] BioLineRx Ltd, Modiin Technol Pk 2,HaMaayan St, Modiin, Israel
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
AML; FLT3-ITD; dual MEK1-FLT3 inhibitor; peptidic CXCR4-antagonist; leukemia-stroma interactions;
D O I：
10.1016/j.clml.2017.07.049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-033
引用
收藏
页码：S273 / S273
页数：1
相关论文
共 50 条
  • [21] Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia
    Kim, Miryoung
    Williams, Sherry
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (04) : 364 - 369
  • [22] FLT3 TYROSINE KINASE DOMAIN (TKD) MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
    Markova, J.
    Michkova, P.
    Maaloufova, J.
    Cetkovsky, P.
    Schwarz, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 550 - 550
  • [23] Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
    Hu, Chuhong
    Zhang, Yvyin
    Yang, Jie
    Xu, Yanli
    Deng, Tingfen
    Li, Yumiao
    Xu, Shilin
    Wang, Shunqing
    Wang, Peihong
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [24] Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients
    Reed, Daniel R.
    Sen, Jeremy M.
    Pierce, Eric J.
    Elsarrag, Ramey Z.
    Keng, Michael K.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (05) : 1200 - 1212
  • [25] Molecular Involvement and Prognostic Importance of Fms-like Tyrosine Kinase 3 in Acute Myeloid Leukemia
    Shahab, Sadaf
    Shamsi, Tahir S.
    Ahmed, Nuzhat
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (09) : 4215 - 4220
  • [26] A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia
    Bazinet, Alexandre
    Bataller, Alex
    Kadia, Tapan
    Daver, Naval
    Short, Nicholas J.
    Yilmaz, Musa
    Sasaki, Koji
    Dinardo, Courtney D.
    Borthakur, Gautam M.
    Issa, Ghayas
    Bouligny, Ian
    Pierce, Sherry
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kantarjian, Hagop M.
    CANCER, 2025, 131 (06)
  • [27] Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia
    Stansfield, Lindsay C.
    Pollyea, Daniel A.
    PHARMACOTHERAPY, 2017, 37 (12): : 1586 - 1599
  • [28] Antitumor triazoloacridinone C-1305 as a potent FLT3 tyrosine kinase inhibitor in human acute myeloid leukemia (AML) cells
    Augustin, E.
    Skwarska, A.
    Koprowska, J.
    Pelikant, I.
    Konopa, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 113 - 113
  • [29] FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia
    Perello-Reus, Catalina M.
    Catala, Albert
    Caviedes-Cardenas, Liska
    Vega-Garcia, Nerea
    Camos, Mireia
    Perez-Torras, Sandra
    Pastor-Anglada, Marcal
    PHARMACOLOGICAL RESEARCH, 2020, 151
  • [30] Implementing RNAi Therapy Targeting FLT3 in Acute Myeloid Leukemia (AML)
    Ansari, Aysha
    Bahadur, Remant K. C.
    Nasrullah, Mohammad
    Sundaram, Daniel N. M.
    Burbano, Luis Morales
    Brandwein, Joseph
    Jiang, Xiaoyan
    Uludag, Hasan
    BLOOD, 2022, 140 : 7791 - 7792
12345